Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34451776)
Watch
English
Oral therapies for diabetic hyperglycemia
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Oral therapies for diabetic hyperglycemia
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
main subject
hyperglycemia
1 reference
based on heuristic
inferred from title
author name string
Lebovitz HE
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
publication date
1 December 2001
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
published in
Endocrinology and Metabolism Clinics of North America
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
volume
30
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
issue
4
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
page(s)
909-933
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
cites work
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Metformin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rosiglitazone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Metformin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association of fasting glucose levels with a delayed secretion of insulin after oral glucose in subjects with glucose intolerance.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diabetes, coronary heart disease and sulphonylureas-not the final word
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Undiagnosed NIDDM: clinical and public health issues.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Insulin resistance: definition and consequences
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Insulin resistance and its treatment by thiazolidinediones
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Repaglinide versus glyburide: a one-year comparison trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An overview of the safety and tolerance of glimepiride
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Individual sulfonylureas and serious hypoglycemia in older people.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rates of hypoglycemia in users of sulfonylureas.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatic dysfunction associated with troglitazone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The PPARs: from orphan receptors to drug discovery
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0889-8529(05)70221-8
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
PubMed ID
11727405
1 reference
stated in
Europe PubMed Central
PubMed ID
11727405
retrieved
2 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit